SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

SGP8

Cat. No.:	HY-P6177
CAS No.:	855790-98-6
Molecular Formula:	$C_{34}H_{58}N_8O_{11}$
Molecular Weight:	754.87
Sequence:	Ile-Ala-Val-Pro-Gly-Glu-Val-Ala
Sequence Shortening:	IAVPGEVA
Target:	Dipeptidyl Peptidase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SGP8 (IAVPGEVA) is an octopeptide derived from the hydrolysis of soybean 11S globulin. SGP8 (IAVPGEVA) has the role of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway. SGP8 (IAVPGEVA) has the ability to inhibit the non-alcoholic steatohepatitis (NASH) [1].
IC_{50} & Target	DPP-4

In Vitro

SGP8 (0,100 and 500 μM; 24 h) has regulatory effects on lipid metabolism, inflammation, and fibrosis [1].
SGP8 (0,100 and 500 μM; 24 h) increases significantly the serum GLP-1 content and targets DPP4 with an inhibitory activity[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR[1]

Cell Line:	L02 cells
Concentration:	0,100 and 500 μM
Incubation Time:	24h
Result:	Improved the mRNA expression of lipid metabolism genes related to Cd36, Scd1, Cpt1 and Pparα and significantly reduced the mRNA expression of inflammatory genes Tnfα, Il-1β, and Ccl5.

Western Blot Analysis[1]

Cell Line:	L02 cells
Concentration:	0,100 and 500 μM
Incubation Time:	24h
Result:	Reduced the expression of lipid metabolism genes related to CD36, FAS, and SREBP-1 compared to the 1 mM PO model group.

Immunofluorescence[1]

Cell Line:	LX2 cells
Concentration:	0 and 500 μM
Incubation Time:	24h
Result:	Reduced effectively TGFβ1-induced expression of α-SMA and Collagen I protein expression.

In Vivo

SGP8 (15 mg/kg, ip; everyday for four weeks) can alleviate MCD diet-induced steatohepatitis in mice[1].
SGP8 (15 mg/kg, ip; everyday for eight weeks) mitigates HFD-induced hepatic injury and metabolic disorders in mice[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Healthy 7-week-old male C57BL/6J mice (22 and 27 g)[1]
Dosage:	15 mg/kg; everydays for four weeks
Administration:	i.g.
Result:	Did not reverse the weight loss of mice caused by the MCD diet. Reduces the ratio of liver weight to body weight, as well as liver TG and TC content. Reduces the activities of ALT and AST in the serum of MCD dietinduced NASH mice. Improved liver fibrosis in MCD diet-induced NASH mice.

REFERENCES

[1]. Peng Ma,et al. IAVPGEVA: Orally Available DPP4-Targeting Soy Glycinin Derived Octapeptide with Therapeutic Potential in Nonalcoholic Steatohepatitis.Journal of Agricultural and Food Chemistry. 2024, 72, 13, 7167–7178.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA